Novo Nordisk's CagriSema Trial Demonstrates Significant Weight Loss

A Phase 3 trial of Novo Nordisk's investigational drug CagriSema, combining cagrilintide and semaglutide, showed an average weight loss of approximately 21% over 68 weeks in adults with overweight or obesity. Lower doses of the drug also led to significant reductions in abdominal fat. These findings, presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology, could offer a new treatment option for obesity management.